Alcon Announces Results of 2024 Annual General Meeting

Rhea-AI Summary

Alcon Inc. announced the successful approval of all proposed resolutions at its 2024 Annual General Meeting. This includes the approval of a dividend of CHF 0.24 per share, re-election of F. Michael Ball as Chair of the Board of Directors, approval of the Board and Executive Committee compensation, and acceptance of financial reports. Shareholders also re-elected other members of the Board and committees, granted discharge to Board and Executive Committee members, and re-elected auditors.

Positive

• Successful approval of all proposed resolutions at the 2024 Annual General Meeting

• Approval of a dividend of CHF 0.24 per share

• Re-election of F. Michael Ball as Chair of the Board of Directors

• Shareholders confirming other members of the Board and committees

• Granting discharge to Board and Executive Committee members for the 2023 financial year

• Re-election of auditors for the 2024 financial year

Negative

• The 2023 Compensation Report was not accepted in a consultative, non-binding vote

• Shareholders approve dividend of CHF 0.24 per share
• Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election
• Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote
• Shareholders approve the Board and Executive Committee compensation in separate binding votes

GENEVA--(BUSINESS WIRE)-- Regulatory News:

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM).

A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,068,314.80, were represented at today's AGM.

Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who all stood for re-election, namely Lynn Bleil, Raquel Bono, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel and Dieter Spälti, for a term of one year.

In addition, shareholders re-elected Thomas Glanzmann, Karen May, Scott Maw and Ines Pöschel to form the Compensation Committee for a period of one year.

Discharge was granted to the members of the Board of Directors and the members of the Executive Committee for the 2023 financial year.

In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2025 Annual General Meeting, and the Executive Committee for 2025 financial year.

Shareholders also accepted the 2023 Non-Financial Matters Report in a non-binding, consultative vote.

Additionally, the 2023 Compensation Report was not accepted in a consultative, non-binding vote.

Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023.

Shareholders also approved that a gross dividend of CHF 0.24 per dividend-bearing share be declared, and that, after appropriation of the proposed dividend, the remaining amount of available earnings be carried forward.

Pricewaterhouse Coopers SA, Geneva, was re-elected as statutory auditors for the 2024 financial year. Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative for a term of one year extending until the 2025 AGM.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Connect with us on
Facebook
LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508352625/en/

Investor Relations

Dan Cravens

Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com

Media Relations

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 615 2501 (Fort Worth)

globalmedia.relations@alcon.com

Source: Alcon Inc. Swiss

FAQ

What dividend per share did shareholders approve at the 2024 Annual General Meeting?

Shareholders approved a dividend of CHF 0.24 per share.

Who was re-elected as Chair of the Board of Directors at the 2024 Annual General Meeting?

F. Michael Ball was re-elected as Chair of the Board of Directors.

What reports were approved by shareholders at the 2024 Annual General Meeting?

Shareholders approved the 2023 Non-Financial Matters Report, operating and financial review, annual financial statements, and consolidated financial statements for 2023.

Which firm was re-elected as statutory auditors for the 2024 financial year?

Pricewaterhouse Coopers SA, Geneva, was re-elected as statutory auditors for the 2024 financial year.

What was the outcome of the vote on the 2023 Compensation Report at the 2024 Annual General Meeting?

The 2023 Compensation Report was not accepted in a consultative, non-binding vote.